Shelter Pharma
SHELTERPHARMALTD NSE
Shelter Pharma
HealthcareNSE: SHELTERPHARMALTD BSE: SHELTER Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹51.50 Cr
Volatility
Moderate
P/E Ratio
5.7
EBITDA
₹12.72 Cr
Return on Equity
16.94%
Debt to Equity
0.01
Book Value
₹43.16
EPS
₹5.36
52W High
₹46.88
52W Low
₹23
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.67 times its book value
Weaknesses
1- Promoter holding has decreased over last quarter: -2.81%
Growth Rate
Revenue Growth
44.24% higher than
3Y
Net Income Growth
25.69% higher than
3Y
Cash Flow Change
380% higher than
3Y
ROE
-2.14% lower than
3Y
ROCE
-1.88% higher than
3Y
EBITDA Margin (Avg.)
-12.53% higher than
3Y
Quarterly Results
| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17.02 | 19.13 | 19.31 | 20.71 | 24.06 | 26.6 | 33.29 | 39.84 |
| Expenses | 13.71 | 14.82 | 15.02 | 16.42 | 19.16 | 21.42 | 27.03 | 33.37 |
| Operating Profit | 3.31 | 4.31 | 4.29 | 4.29 | 4.9 | 5.18 | 6.26 | 6.47 |
| OPM % | 19.45% | 22.53% | 22.22% | 20.71% | 20.37% | 19.47% | 18.8% | 16.24% |
| Other Income | 0 | -0.45 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| Interest | 0.01 | 0.01 | 0.05 | 0 | 0.07 | 0.06 | 0.06 | 0.05 |
| Depreciation | 0.08 | 0.08 | 0.12 | 0.13 | 0.1 | 0.17 | 0.19 | 0.22 |
| PBT | 3.22 | 3.77 | 4.12 | 4.16 | 4.73 | 4.95 | 6.01 | 6.21 |
| Tax % | 25.47% | 25.46% | 24.76% | 25% | 25.16% | 25.05% | 25.29% | 27.05% |
| Net Profit | 2.4 | 2.81 | 3.1 | 3.12 | 3.54 | 3.7 | 4.5 | 4.53 |
| EPS in Rs | 49.59 | 3.63 | 2.68 | 2.7 | 3.06 | 3.2 | 3.89 | 2.73 |
Profit & Loss
| Particulars | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.09 | 29.95 | 30.07 | 22.48 | 30.06 | 36.15 | 39.93 | 50.64 | 73.02 |
| Expenses | 27.94 | 30.65 | 29.83 | 22.29 | 27.01 | 28 | 31.14 | 40.57 | 60.29 |
| Operating Profit | 0.15 | -0.7 | 0.24 | 0.19 | 3.05 | 8.15 | 8.79 | 10.07 | 12.73 |
| OPM % | 0.53% | -2.34% | 0.8% | 0.85% | 10.15% | 22.54% | 22.01% | 19.89% | 17.43% |
| Other Income | 0 | 0.83 | 0.01 | 0.01 | 0 | -0.97 | 0 | 0.01 | 0.02 |
| Interest | 0 | 0 | 0.01 | 0.02 | 0.08 | 0.03 | 0.26 | 0.13 | 0.12 |
| Depreciation | 0.1 | 0.07 | 0.13 | 0.12 | 0.17 | 0.16 | 0.25 | 0.27 | 0.41 |
| PBT | 0.05 | 0.06 | 0.11 | 0.06 | 2.8 | 6.99 | 8.28 | 9.68 | 12.22 |
| Tax % | 20% | 16.67% | 27.27% | 33.33% | 26.79% | 25.46% | 25.12% | 25.21% | 26.19% |
| Net Profit | 0.05 | 0.05 | 0.08 | 0.04 | 2.06 | 5.21 | 6.2 | 7.24 | 9.03 |
| EPS in Rs | 1.1 | 1.1 | 1.76 | 0.83 | 42.56 | 6.73 | 5.36 | 6.26 | 5.44 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.45 | 0.45 | 0.45 | 0.48 | 0.48 | 7.74 | 11.56 | 11.56 | 16.61 |
| Reserves | 7.31 | 7.32 | 6.53 | 6.63 | 8.32 | 6.81 | 24.26 | 31.16 | 60.02 |
| Borrowings | 2.07 | 0.11 | 0.24 | 0 | 0.13 | 1.78 | 0.58 | 1.04 | 0.8 |
| Other Liabilities | 1.73 | 3.76 | 3.41 | 3.09 | 3.91 | 5.12 | 1.51 | 4.58 | 6.8 |
| Total Liabilities | 11.56 | 11.64 | 10.63 | 10.2 | 12.84 | 21.45 | 37.91 | 48.34 | 84.23 |
| Fixed Assets | 2.61 | 2.71 | 1.77 | 1.57 | 1.45 | 2.52 | 4.26 | 5.96 | 7.14 |
| CWIP | 0.14 | 0.11 | 0 | 0 | 0.55 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0.68 | 0.68 | 0.68 | 0 | 0 | 0.68 | 0.68 |
| Other Assets | 8.81 | 8.82 | 8.18 | 7.95 | 10.16 | 18.93 | 33.65 | 41.7 | 76.41 |
| Total Assets | 11.56 | 11.64 | 10.63 | 10.2 | 12.84 | 21.45 | 37.91 | 48.34 | 84.23 |
Cash Flow
| Particulars | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | — | 0 | -0.27 | -0.28 | 0.52 | 0 | -1.96 | 5.42 | -12.48 |
| Investing | — | 0 | 0.29 | 0.03 | -0.85 | 0.11 | -4.43 | -7.13 | -14.55 |
| Financing | — | 0 | 0 | 0.48 | 0.06 | 0.21 | 11.01 | 0.09 | 24.69 |
| Net Cash Flow | — | 0 | 0.02 | 0.23 | -0.27 | 0.33 | 4.61 | -1.62 | -2.34 |
| Free Cash Flow | — | 0 | -0.32 | -0.29 | -0.08 | 0 | -2.81 | 2.77 | -14.07 |
| CFO/OP | — | 0 | -112 | -147 | 17 | 0 | -5 | 78 | -73 |
Ratios
| Particulars | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.99 | 14.14 | 7.4 | 12.34 | 19.55 | 82.69 | 80.9 | 68.26 | 59.03 |
| Inventory Days | 61.39 | 49.67 | 55.59 | 69.41 | 80.06 | 111 | 125 | 127 | 161 |
| Days Payable | 2.49 | 2.16 | 3.35 | 5.35 | 4.52 | 6.54 | 8.96 | 12.32 | 8.21 |
| Cash Conversion Cycle | 71.89 | 61.65 | 59.64 | 76.4 | 95.09 | 187 | 197 | 183 | 211 |
| Working Capital Days | 91.35 | 59.59 | 54.14 | 74.85 | 71.64 | 122 | 212 | 182 | 235 |
| ROCE % | — | 0.68% | — | 1.12% | 35.91% | 63.26% | 32.39% | 24.48% | 20.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Shelter Pharma insights
60 extracted metrics + investor summaries across FY16–FY26.
Documents
1
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015- New Product Launch.
16h - Shelter Pharma launched FOLIMAN folic acid tablets on May 11, 2026 for international markets. 16h - Shelter Pharma launched FOLIMAN folic acid tablets on May 11, 2026 for international markets.
2
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
5 May - Shelter Pharma received repeat international orders from Taha Drugs for nutraceuticals worth USD 84,450. 5 May - Shelter Pharma received repeat international orders from Taha Drugs for nutraceuticals worth USD 84,450.
3
Announcement under Regulation 30 (LODR)-Conversion of Securities
5 May - Board approved conversion of 111,000 warrants into equity shares, raising ₹35.17 lakh; capital increased to 1,68,36,792 shares. 5 May - Board approved conversion of 111,000 warrants into equity shares, raising ₹35.17 lakh; capital increased to 1,68,36,792 shares.
4
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, May 05, 2026 For Conversion Of 111000 Warrants Into 111000 Equity Shares Of Face Value Of Rs. 10/-
5 May - Board approved conversion of 111,000 warrants into equity shares, raising paid-up capital to ₹16.84 crore. 5 May - Board approved conversion of 111,000 warrants into equity shares, raising paid-up capital to ₹16.84 crore.
5
Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, May 01, 2026.
1 May - Board approved conversion of 2,79,000 warrants into 1,14,000 equity shares on May 1, 2026. 1 May - Board approved conversion of 2,79,000 warrants into 1,14,000 equity shares on May 1, 2026.
Frequently Asked Questions about Shelter Pharma
What does Shelter Pharma Ltd do?
Incorporated in 2007, Shelter Pharma Ltd manufactures pharma products including
food supplements for animals[1]
Where is Shelter Pharma Ltd (543963) listed?
Shelter Pharma Ltd trades as SHELTERPHARMALTD on the NSE and under code SHELTER on the BSE.
Which sector does Shelter Pharma Ltd belong to?
Shelter Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Shelter Pharma Ltd?
Shelter Pharma Ltd has a market capitalisation of ₹51.5 Cr, which places it in the Small Cap band.
What is the PE ratio of Shelter Pharma Ltd?
Shelter Pharma Ltd trades at a PE ratio of 5.70, on earnings per share of ₹5.36, against a book value of ₹43.16 per share.
What is the 52-week high and low of Shelter Pharma Ltd?
Over the last 52 weeks Shelter Pharma Ltd has traded between ₹23 and ₹46.88.
Does Shelter Pharma Ltd pay dividends?
Shelter Pharma Ltd has a dividend yield of 1.14%.
What is the Return on Equity (ROE) of Shelter Pharma Ltd?
Shelter Pharma Ltd reported a return on equity of 16.94%. Its debt-to-equity ratio is 0.01.
Company Information
Incorporated in 2007, Shelter Pharma Ltd manufactures pharma products including food supplements for animals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543963.md for Shelter Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.